EU Clinical Trial 2018-002823-41

A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension.  Mar 25, 2019

Main objective of the trial: The primary objective of the study is to evaluate the effect of selexipag on pulmonary vascular resistance (PVR) versus placebo in subjects with inoperable CTEPH and persistent/recurrent CTEPH after surgical treatment (pulmonary endarterectomy [PEA] and/or balloon pulmonary angioplasty [BPA]) at Week 20.

Parties

Sponsors